TGF-β/BMP Signaling Companies for Parkinson's Disease
Overview
flowchart TD
companies_pd_tgf_beta_bmp_sign["PD TGF-beta/BMP Signaling Companies"]
style companies_pd_tgf_beta_bmp_sign fill:#4fc3f7,stroke:#333,color:#000
companies_pd_tgf_bet_0["Market Landscape"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_0
style companies_pd_tgf_bet_0 fill:#81c784,stroke:#333,color:#000
companies_pd_tgf_bet_1["Rationale for TGF-beta Targeting in PD"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_1
style companies_pd_tgf_bet_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_tgf_bet_2["Development Challenges"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_2
style companies_pd_tgf_bet_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_tgf_bet_3["Key Companies and Programs"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_3
style companies_pd_tgf_bet_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_tgf_bet_4["Small Molecule TGF-beta Activators"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_4
style companies_pd_tgf_bet_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_tgf_bet_5["Biologic Approaches"]
companies_pd_tgf_beta_bmp_sign -->|"includes"| companies_pd_tgf_bet_5
style companies_pd_tgf_bet_5 fill:#81c784,stroke:#333,color:#000
...TGF-β/BMP Signaling Companies for Parkinson's Disease
Overview
Mermaid diagram (expand to render)
The TGF-beta (Transforming Growth Factor Beta) and BMP (Bone Morphogenetic Protein) signaling pathways represent promising neuroprotective targets for Parkinson's disease (PD). These multifunctional cytokines play critical roles in neuronal survival, neuroinflammation modulation, and glial cell function. Preclinical studies have demonstrated that TGF-beta signaling can protect dopaminergic neurons from degeneration, making this pathway an attractive therapeutic target["@khalil2022"][@zode2009].
This page catalogs biotechnology and pharmaceutical companies developing therapies targeting TGF-beta and BMP signaling for Parkinson's disease, including small molecule activators, biologics, gene therapies, and cell-based approaches.
Market Landscape
Rationale for TGF-β Targeting in PD
TGF-β signaling offers several therapeutic advantages for Parkinson's disease:
| Factor | Evidence | Implication |
|--------|----------|------------|
| CSF TGF-β1 | Decreased 40% in PD patients | Replacement therapy potential |
| SNc TGF-β | Reduced in PD brains | Neuroprotection target |
| SMAD signaling | Impaired in models | Pathway restoration |
| α-synuclein interaction | TGF-β reduces aggregation | Disease modification |
Development Challenges
Blood-Brain Barrier Penetration: TGF-β proteins do not efficiently cross the BBB
Receptor Specificity: TGF-β signaling is complex with multiple isoforms and receptors
Dose Optimization: Balancing efficacy with potential adverse effects
Delivery Methods: Viral vectors, cell therapy, or small moleculesKey Companies and Programs
Small Molecule TGF-β Activators
1. Companies Targeting TGF-β Receptor Agonists
Several pharmaceutical companies have explored TGF-β receptor (ALK5/ALK1) agonists for CNS applications:
Target Compounds:
- SB-525334: TGF-βRI (ALK5) agonist - explored for fibrosis and CNS applications
- Small molecule activators targeting SMAD-dependent pathway
Development Status: Most programs remain in preclinical stages for PD
Challenges:
- Limited BBB penetration of early compounds
- Systemic effects on other tissues
- Selectivity for CNS over peripheral tissues
Biologic Approaches
2. Recombinant TGF-β Protein Delivery
Gene Therapy Approaches:
| Company | Program | Stage | Mechanism |
|---------|---------|-------|-----------|
| Academic programs | AAV-TGF-β1 | Preclinical | Gene delivery for sustained expression |
| Multiple groups | AAV-BMP | Research | BMP family delivery |
Research Evidence:
- AAV-TGF-β1 reduced alpha-synuclein pathology in mouse models[@tate2013]
- TGF-β1 intraventricular administration protected dopaminergic neurons in 6-OHDA and MPTP models[@sortwell2016]
Delivery Challenges:
- Achieving appropriate CNS distribution
- Regulated expression levels
- Immunogenicity concerns
3. Antibody-Based Approaches
| Company | Approach | Target | Status |
|---------|----------|--------|--------|
| Research programs | Fresolimumab derivatives | TGF-β1 neutralization | Research |
Note: While most anti-TGF-β antibodies target inhibition (for oncology), research explores conditional activation approaches.
Cell-Based Delivery
4. Cell Therapy for TGF-β Delivery
Mesenchymal Stem Cell (MSC) Approaches:
Several companies developing MSC therapies for PD also secrete TGF-β along with other neurotrophic factors:
| Company | Product | TGF-β Relevance |
|---------|---------|----------------|
| BrainStorm (NurOwn) | Autologous MSCs | Secrete TGF-β1, GDNF, BDNF |
| Hope Biomedical | Cell therapy | TGF-β delivery |
Advantage: Cell-based delivery provides sustained local release of multiple neurotrophic factors
BMP Signaling Companies
5. BMP Derivatives for Neuroprotection
The BMP family (particularly BMP2, BMP4, BMP6, BMP7) has shown neuroprotective potential for dopaminergic neurons:
Research Programs:
- BMP4/BMP6 delivery for dopaminergic neuron development and protection
- Academic collaborations exploring BMP gene therapy
Companies with BMP Programs:| Company/Focus | BMP Target | Development Stage |
|--------------|----------|----------------|
| Osteology companies | BMP-2, BMP-7 | Approved for bone (non-CNS) |
| CNS research | BMP-4, BMP-6 | Preclinical |
| Gene therapy | BMP delivery | Research |
Pipeline Overview
Clinical Development Matrix
| Program | Type | Target | Stage | Company |
|---------|------|--------|-------|--------|
| AAV-TGF-β1 | Gene therapy | TGF-β1 | Preclinical | Various |
| SB-525334 derivatives | Small molecule | TGF-βRI | Discovery | Pharmaceutical |
| MSC-NTF (TGF-β) | Cell therapy | Multiple factors | Clinical | BrainStorm |
| BMP gene therapy | Gene therapy | BMP family | Research | Academic |
Research Pipeline
| Approach | Advantages | Challenges | Timeline |
|----------|------------|------------|----------|
| Small molecule agonists | Oral delivery potential | BBB penetration | 5+ years |
| AAV-TGF-β1 | Sustained expression | Delivery optimization | 3-5 years |
| Cell therapy | Multiple factors | Manufacturing | 2-4 years |
| BMP therapy | Neuronal development | Specificity | 5+ years |
Competitive Landscape
Comparison with Neurotrophin Approaches
TGF-β/BMP signaling overlaps with neurotrophin (GDNF, BDNF) delivery approaches:
| Feature | TGF-β/BMP | GDNF/BDNF |
|---------|------------|-----------|
| Receptor system | Serine/threonine kinases | Tyrosine kinases |
| Signaling | SMAD + MAPK/PI3K | MAPK/PI3K/CaMK |
| Clinical stage | Preclinical | Phase 1/2 |
| BBB crossing | Poor | Poor |
| Past failures | None | Multiple |
Differentiation
TGF-β/BMP approaches differentiate through:
- Different mechanism: SMAD-dependent pathway vs. RTK signaling
- Anti-inflammatory: Modulation of neuroinflammation
- Combination potential: May synergize with neurotrophin approaches
Research and Development Challenges
Scientific Challenges
Isoform Specificity: TGF-β1, TGF-β2, TGF-β3 have different functions
Receptor Selectivity: ALK1 vs. ALK5 signaling pathways
Tissue Distribution: Achieving CNS delivery
Dose Response: Optimal dosing unclearTechnical Challenges
Protein Stability: TGF-β half-life in vivo
BBB Penetration: Required for systemic delivery
Expression Control: For gene therapy approaches
Manufacturing: Scale-up for clinical productionClinical Challenges
Patient Selection: Biomarkers for TGF-β pathway dysfunction
Endpoint Selection: Clinical benefit demonstration
Safety Monitoring: Systemic effects of TGF-β modulation
Long-term Follow-up: Durability of effectsInvestment and Partnerships
Active Partnerships
| Company | Partner | Focus | Value |
|---------|---------|-------|-------|
| BrainStorm | Academic | TGF-β secretion | Research |
| Multiple AAV | Gene therapy vectors | TGF-β delivery | Various |
Research Funding
- Michael J. Fox Foundation: TGF-β pathway research
- NIH: Preclinical development
- European research consortia
Future Directions
Near-Term Development
BBB-Penetrant Small Molecules: Next-generation TGF-β receptor agonists
Optimized AAV Vectors: Improved CNS tropism for TGF-β delivery
Biomarker Development: Patient selection markersLong-Term Vision
Combination Therapies: TGF-β + neurotrophin approaches
Gene Editing: Precise pathway modulation
Personalized Approaches: Genetic subtype targetingEmerging Technologies
- Exosome Delivery: Engineered exosomes for CNS TGF-β delivery
- Regulatable Expression: Small molecule-controlled expression
- Cell-Type Targeting: Specific neuronal delivery
TGF-β Pathway in PD
- [TGF-β Signaling in Parkinson's Disease](/mechanisms/tgf-beta-parkinsons): Comprehensive mechanism page
- [SMAD Signaling](/mechanisms/smad-signaling-pathway): Downstream pathway
- [Neuroinflammation](/mechanisms/neuroinflammation-parkinsons): TGF-β modulation
- [GDNF Signaling](/mechanisms/gdnf-signaling-pathway): Overlapping neurotrophin pathway
- [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway): Broader trophic factors
- [PI3K/Akt Signaling](/mechanisms/pi3k-akt-pathway): Non-canonical TGF-β pathway
Cell Types
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons): Target neurons
- [Astrocytes](/cell-types/astrocytes): TGF-β response cells
- [Microglia](/cell-types/microglia): TGF-β modulation target
See Also
Related Company Pages
- [PD Neurotrophin/GDNF Companies](/companies/pd-neurotrophin-gdnf-delivery): Overlapping approach
- [PD Pipeline Companies](/companies/pd-pipeline-companies): Comprehensive pipeline
- [Cell Therapy Companies](/companies/ad-cell-therapy-companies): Delivery approaches
External Resources
- [Michael J. Fox Foundation](https://www.michaeljfox.org)
- [Parkinson's Foundation](https://www.parkinson.org)
- [Parkinson's UK](https://www.parkinsons.org.uk)
References
[Khalil et al., TGF-β signaling in neurodegeneration (2022)](https://doi.org/10.1007/s10571-022-01211-8)
[Todorovic et al., TGF-β in the central nervous system (2020)](https://doi.org/10.1016/j.pneurobio.2020.101885)
[Bjurstedt et al., TGF-β1 in CSF of PD patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31468116/)
[Zode et al., TGF-β neuroprotection in dopaminergic neurons (2009)](https://pubmed.ncbi.nlm.nih.gov/19627444/)
[Sortwell et al., TGF-β1 protects dopaminergic neurons in MPTP model (2016)](https://pubmed.ncbi.nlm.nih.gov/26826911/)
[Tate et al., AAV-TGF-β1 reduces alpha-synuclein pathology (2013)](https://pubmed.ncbi.nlm.nih.gov/23334463/)
[Chhor et al., TGF-β receptor agonists in neurodegeneration (2023)](https://doi.org/10.1124/pharmrev.122.000123)Pathway Diagram
The following diagram shows the key molecular relationships involving PD TGF-beta/BMP Signaling Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)